Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG: Significant strengthening of the patent protection for the sepsis drug candidate Adrecizumab
Deutsche Biotech Innovativ AG / Key word(s): Patent CORPORATE NEWS Deutsche Biotech Innovativ AG: Significant strengthening of the patent protection for the sepsis drug candidate Adrecizumab Hennigsdorf, 21 July 2015 – Deutsche Biotech Innovativ AG (“DBI”) has significantly strengthened the patent protection for its main drug candidate Adrecizumab. The biotechnology company based near Berlin has received the notice of allowance from the United States Patent and Trademark Office (USPTO) for the key patent, which provides comprehensive protection in the treatment of sepsis, shock and systemic inflammatory response syndrome (SIRS) by the drug candidate Adrecizumab. Following the granting of essential patents for Adrecizumab within the European Union in 2014, the DBI’s business is now comprehensively protected in the most important markets until the year 2032 at the very least. DBI has therefore reached another strategically important milestone on the path towards strengthening its market position in the area of sepsis treatment. “The notice of allowance in relation to the US patent is a key component of our strategic patent portfolio and ensures effective market protection for our first-in-class agent for the treatment of sepsis,” commented DBI board member Dr. Bernd Wegener. About Adrecizumab About Deutsche Biotech Innovativ AG The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders’ and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the development of blood biomarkers for diagnosis and therapy monitoring of serious diseases, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For further information please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG 2015-07-21 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
379449 2015-07-21 |